Persantin 100mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Dipyridamole

Available from:

Boehringer Ingelheim Ltd

ATC code:

B01AC07

INN (International Name):

Dipyridamole

Dosage:

100mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 02090000; GTIN: 5012816070318

Patient Information leaflet

PERSANTIN 100MG TABLETS
(dipyridamole)
PATIENT INFORMATION LEAFLET
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE
*
Keep this leaflet. You may need to read it again.
*
If you have any further questions, ask your doctor or pharmacist
*
This medicine has been prescribed for you. Do not pass it on to
others. It
may harm them, even if their symptoms are the same as yours.
*
If any of the side effects gets troublesome or serious, or if you
notice any
side effects not listed in this leaflet, please tell your doctor or
pharmacist.
Your medicine is called Persantin 100mg Tablets, but will be reffered
to as
Persantin Tablets throughout this leaflet.
IN THIS LEAFLET:
What Persantin Tablets are and what they are used for
Before you take Persantin Tablets
How to take Persantin Tablets
Possible side effects
How to store Persantin Tablets
Further information
WHAT PERSANTIN TABLETS ARE AND WHAT THEY ARE USED
FOR
The name of your medicine is Persantin Tablets. It contains a medicine
called Dipyridamole. This belongs to a group of medicines called
‘anti-thrombotic agents’, which are used to help stop blood clots
forming.
Persantin Tablets help stop blood clots which may occur if you have
had
your heart valves replaced.
BEFORE YOU TAKE PERSANTIN TABLETS
DO NOT TAKE PERSANTIN TABLETS IF YOU ARE ALLERGIC (HYPERSENSITIVE) TO:
*
Dipyridamole
Any of the other ingredients of Persantin Tablets (see section 6:
Further
information)
TAKE SPECIAL CARE WITH PERSANTIN TABLETS
Check with your doctor or pharmacist before taking your medicine if:
*
You have angina or other heart problems (including heart valve or
circulation problems) or have had a recent heart attack
*
You have myasthenia gravis (a rare muscle problem)
*
You have any bleeding problems
*
You are pregnant or planning to become pregnant or are breast-feeding
*
You have been told by your doctor that you have an intolerance to some
sugars
If you are not sure if any of the above apply to you, talk to your
doctor or
pharmacist before taking Persantin Table

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
PERSANTIN Tablets 100 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Dipyridamole 100 mg.
For excipients, see 6.1.
3.
PHARMACEUTICAL FORM
Coated Tablets.
Round, white, biconvex, shiny, sugar-coated tablets.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
An adjunct to oral anti-coagulation for prophylaxis of
thrombo-embolism
associated with prosthetic heart valves.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
_Adults: _
300-600 mg daily in three or four doses.
_Children: _
PERSANTIN is not recommended for children.
PERSANTIN should usually be taken before meals.
4.3
CONTRAINDICATIONS
Hypersensitivity to any of the components of the product.
In case of rare hereditary conditions that may be incompatible with an
excipient of
the product (please refer to Special warnings and precautions for use)
the use of the
product is contraindicated.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Among other properties, dipyridamole acts as a vasodilator. It should
be used with
caution in patients with severe coronary artery disease, including
unstable angina
and/or recent myocardial infarction, left ventricular outflow
obstruction or
haemodynamic instability (e.g. decompensated heart failure).
Patients being treated with regular oral doses of PERSANTIN should not
receive
additional intravenous dipyridamole. Clinical experience suggests that
patients being
treated with oral dipyridamole who also require pharmacological stress
testing with
intravenous dipyridamole, should discontinue drugs containing oral
dipyridamole for
twenty-four hours prior to stress testing.
In patients with myasthenia gravis, readjustment of therapy may be
necessary after
changes in dipyridamole dosage (see Drug Interactions).
PERSANTIN should be used with caution in patients with coagulation
disorders.
A small number of cases have been reported in which unconjugated
dipyridamole was
shown to be incorporated into gallstones to a variable extent (upto
70% by dry weight
of stone). These pati